Tricalcium phosphate delayed release formulation for oral delivery of insulin: A proof-of-concept study

Journal of Pharmaceutical Sciences

Volumn 97, Issue 2, 2008, Pages 875-882

  Paul, Willi ^a   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Bio ceramics; Diabetes; Eudragit S100; Microspheres; Oral drug delivery; Peptides; Tricalcium phosphate

Indexed keywords

CALCIUM PHOSPHATE; EUDRAGIT; GLUCOSE; HUMAN INSULIN; MICROSPHERE; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN TREATMENT; MALE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; RAT; SIMULATION; STREPTOZOCIN DIABETES; WISTAR RAT;

EID: 39749177298     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21012     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053.
2. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. New Engl J Med 329:977-986.
3. The Diabetes Control and Complications Trial Research Group. 1996. The Absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298.
4. Owens DR, Zinman B, Bolli G. 2003. Alternative routes of insulin delivery. Diabet Med 20:886-898.
5. Kumar TR, Soppimath K, Nachaegari SK. 2006. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 7:261-276.
6. Raj NKK, Sharma CP. 2003. Oral insulin - A perspective. J Biomat Appl 17:183-196.
7. Sah H. 1999. Protein behaviour at the water/methylene chloride interface. J Pharm Sci 88:1320-1325.
8. Sah H. 1999. Protein instability toward organic solvent/water emulsification: Implications for protein microencapsulation into microspheres. PDA J Pharm Sci Tech 53:3-10.
9. Paul W, Sharma CP. 2003. Ceramic drug delivery: A perspective. J Biomat Appl 17:253-264.
10. Hnatyszyn JH, Kossovsky N, Gelman A, Sponsler E. 1994. Drug delivery systems for the future. PDA J Pharm Sci Technol 48:247-254.
11. Paul W, Sharma CP. 1999. Development of porous spherical hydroxyapatite granules: Application towards protein delivery. J Mater Sci Mater Med 10:383-388.
12. Paul W, Jerry N, Sharma CP. 2002. Delivery of insulin from hydroxyapatite ceramic microspheres: Preliminary in vivo studies. J Biomed Mater Res 61:660-662.
13. Bajpai PK, Fuchs CM, McCullum DE. 1988. Development of tricalcium phosphate ceramic cements. In: Lemons JE, editor. Quantitative characterization and performance of porous implants for hard tissue applications, ASTM STP 953. Philadelphia: American Society for Testing and Materials. pp 377-388.
14. Sreerama N, Woody RW. 2000. Estimation of protein secondary structure from circular dichroism spectra: Comparison of CONTIN, SELCON and CDSSTR methods with an expanded reference set. Anal Biochem 287:252-260.
15. Hua Q, Weiss MA. 2004. Mechanism of insulin fibrillation: The structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate. J Biol Chem 279:21449-21460.
16. Trinder P. 1969. Determination of blood glucose using an oxidase-peroxidase system with a noncarcinogenic chemogen. J Clin Pathol 22:158-161.
17. Sharma P, Varma MV, Chawla HP, Panchagnula R. 2005. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60:884-893.
18. Lowes S, Simmons NL. 2001. Human intestinal cell monolayers are preferentially sensitive to disruption of barrier function from basolateral exposure to cholic acid: Correlation with membrane transport and transepithelial secretion. Eur J Physiol 443:265-273.
19. Uchiyama T, Yamamoto A, Hatano H, Fujita T, Muranishi S. 1996. Effectiveness and toxicity screening of various absorption enhancers in the large intestine: Intestinal absorption of phenol red and protein and phospholipid release from the intestinal membrane. Biol Pharm Bull 19:1618-1621.
20. Yamamoto A, Uchiyama T, Nishikawa R, Fujita T, Muranishi S. 1996. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: Effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J Pharm Pharmacol 48:1285-1289.
21. Gómez-Vera J, de Alarcón A, Jiménez-Meji'as ME, Acosta D, Prados D, Viciana P. 2000. Hyperglycemia associated with protease inhibitors in HIV-1-infected patients. Clin Microbiol Infect 6:389-392.
22. Kimura T, Sato K, Sugimoto K, Tao R, Murakami T, Kurosaki Y, Nakayama T. 1996. Oral administration of insulin as poly(vinyl alcohol) gel spheres in diabetic rats. Biol Pharm Bull 19:897-900.
23. Dodson G, Steiner D. 1998. The role of assembly in insulin's biosynthesis. Curr Opin Struct Biol 8:189-194.
24. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA, Vijayan M. 1971. Atomic Positions in Rhombohedral 2-Zinc Insulin Crystals. Nature 231:506-511.
25. Michael J, Carroll R, Swift HH, Steiner DF. 1987. Studies on the molecular organization of rat insulin secretory granules. J Biol Chem 262:16531-16535.
26. Prieto J, Wilmans M, Jimenez MA, Rico M, Serrano L. 1997. Non-native local interactions in protein folding and stability: Introducing a helical tendency in the all β-sheet α-spectrin SH3 domain. J Mol Biol 268:760-778.
27. Ahmad A, Millett IS, Doniach S, Uversky VN, Fink AL. 2003. Partially folded intermediates in insulin fibrillation. Biochemistry 42:11404-11416.
28. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL. 2001. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 40:6036-6046.
29. Arbit E. 2004. The physiological rationale for oral insulin administration. Diabetes Technol Ther 6:510-517.
30. Gordon SJ. 2002. Development of oral insulin: Progress and current status. Diabetes Metab Res Rev 18:S29-S37.
31. Morishita M, Goto T, Nakamura K, Lowman AM, Takayama K, Peppas NA. 2006. Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J Control Release 110:587-594.
32. Hussain N, Jaitley V, Florence AT. 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50:107-142.